Cargando…

Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens

Infections by Gram-negative multi-drug resistant (MDR) bacterial species are difficult to treat using available antibiotics. Overuse of carbapenems has contributed to widespread resistance to these antibiotics; as a result, carbapenem-resistant Enterobacterales (CRE), A. baumannii (CRAB), and P. aer...

Descripción completa

Detalles Bibliográficos
Autores principales: Cruz-López, Flora, Martínez-Meléndez, Adrian, Morfin-Otero, Rayo, Rodriguez-Noriega, Eduardo, Maldonado-Garza, Héctor J., Garza-González, Elvira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163340/
https://www.ncbi.nlm.nih.gov/pubmed/35669117
http://dx.doi.org/10.3389/fcimb.2022.884365
_version_ 1784719897009324032
author Cruz-López, Flora
Martínez-Meléndez, Adrian
Morfin-Otero, Rayo
Rodriguez-Noriega, Eduardo
Maldonado-Garza, Héctor J.
Garza-González, Elvira
author_facet Cruz-López, Flora
Martínez-Meléndez, Adrian
Morfin-Otero, Rayo
Rodriguez-Noriega, Eduardo
Maldonado-Garza, Héctor J.
Garza-González, Elvira
author_sort Cruz-López, Flora
collection PubMed
description Infections by Gram-negative multi-drug resistant (MDR) bacterial species are difficult to treat using available antibiotics. Overuse of carbapenems has contributed to widespread resistance to these antibiotics; as a result, carbapenem-resistant Enterobacterales (CRE), A. baumannii (CRAB), and P. aeruginosa (CRPA) have become common causes of healthcare-associated infections. Carbapenems, tigecycline, and colistin are the last resource antibiotics currently used; however, multiple reports of resistance to these antimicrobial agents have been documented worldwide. Recently, new antibiotics have been evaluated against Gram-negatives, including plazomicin (a new aminoglycoside) to treat CRE infection, eravacycline (a novel tetracycline) with in vitro activity against CRAB, and cefiderocol (a synthetic conjugate) for the treatment of nosocomial pneumonia by carbapenem-non-susceptible Gram-negative isolates. Furthermore, combinations of known β-lactams with recently developed β-lactam inhibitors, such as ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime-tazobactam, and meropenem-vaborbactam, has been suggested for the treatment of infections by extended-spectrum β-lactamases, carbapenemases, and AmpC producer bacteria. Nonetheless, they are not active against all carbapenemases, and there are reports of resistance to these combinations in clinical isolates.This review summarizes and discusses the in vitro and clinical evidence of the recently approved antibiotics, β-lactam inhibitors, and those in advanced phases of development for treating MDR infections caused by Gram-negative multi-drug resistant (MDR) bacterial species.
format Online
Article
Text
id pubmed-9163340
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91633402022-06-05 Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens Cruz-López, Flora Martínez-Meléndez, Adrian Morfin-Otero, Rayo Rodriguez-Noriega, Eduardo Maldonado-Garza, Héctor J. Garza-González, Elvira Front Cell Infect Microbiol Cellular and Infection Microbiology Infections by Gram-negative multi-drug resistant (MDR) bacterial species are difficult to treat using available antibiotics. Overuse of carbapenems has contributed to widespread resistance to these antibiotics; as a result, carbapenem-resistant Enterobacterales (CRE), A. baumannii (CRAB), and P. aeruginosa (CRPA) have become common causes of healthcare-associated infections. Carbapenems, tigecycline, and colistin are the last resource antibiotics currently used; however, multiple reports of resistance to these antimicrobial agents have been documented worldwide. Recently, new antibiotics have been evaluated against Gram-negatives, including plazomicin (a new aminoglycoside) to treat CRE infection, eravacycline (a novel tetracycline) with in vitro activity against CRAB, and cefiderocol (a synthetic conjugate) for the treatment of nosocomial pneumonia by carbapenem-non-susceptible Gram-negative isolates. Furthermore, combinations of known β-lactams with recently developed β-lactam inhibitors, such as ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime-tazobactam, and meropenem-vaborbactam, has been suggested for the treatment of infections by extended-spectrum β-lactamases, carbapenemases, and AmpC producer bacteria. Nonetheless, they are not active against all carbapenemases, and there are reports of resistance to these combinations in clinical isolates.This review summarizes and discusses the in vitro and clinical evidence of the recently approved antibiotics, β-lactam inhibitors, and those in advanced phases of development for treating MDR infections caused by Gram-negative multi-drug resistant (MDR) bacterial species. Frontiers Media S.A. 2022-05-20 /pmc/articles/PMC9163340/ /pubmed/35669117 http://dx.doi.org/10.3389/fcimb.2022.884365 Text en Copyright © 2022 Cruz-López, Martínez-Meléndez, Morfin-Otero, Rodriguez-Noriega, Maldonado-Garza and Garza-González https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Cruz-López, Flora
Martínez-Meléndez, Adrian
Morfin-Otero, Rayo
Rodriguez-Noriega, Eduardo
Maldonado-Garza, Héctor J.
Garza-González, Elvira
Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens
title Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens
title_full Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens
title_fullStr Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens
title_full_unstemmed Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens
title_short Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens
title_sort efficacy and in vitro activity of novel antibiotics for infections with carbapenem-resistant gram-negative pathogens
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163340/
https://www.ncbi.nlm.nih.gov/pubmed/35669117
http://dx.doi.org/10.3389/fcimb.2022.884365
work_keys_str_mv AT cruzlopezflora efficacyandinvitroactivityofnovelantibioticsforinfectionswithcarbapenemresistantgramnegativepathogens
AT martinezmelendezadrian efficacyandinvitroactivityofnovelantibioticsforinfectionswithcarbapenemresistantgramnegativepathogens
AT morfinoterorayo efficacyandinvitroactivityofnovelantibioticsforinfectionswithcarbapenemresistantgramnegativepathogens
AT rodrigueznoriegaeduardo efficacyandinvitroactivityofnovelantibioticsforinfectionswithcarbapenemresistantgramnegativepathogens
AT maldonadogarzahectorj efficacyandinvitroactivityofnovelantibioticsforinfectionswithcarbapenemresistantgramnegativepathogens
AT garzagonzalezelvira efficacyandinvitroactivityofnovelantibioticsforinfectionswithcarbapenemresistantgramnegativepathogens